CRO concept stocks continued their recent rebound. As of press release, Pharmaceutical Biotech (02269) rose 5.23% to HK$18.1; Gloria Ying (06821) rose 4.92% to HK$68.25; Pharmachem Kangde (02359) rose 4.64% to HK$47.4; and Kingsley Biotech (01548) rose 4.46% to HK$14.52.
The Zhitong Finance App learned that CRO concept stocks continued their recent rebound. As of press release, Pharmaceutical Biotech (02269) rose 5.23% to HK$18.1; Gloria Ying (06821) rose 4.92% to HK$68.25; Pharmachem Kangde (02359) rose 4.64% to HK$47.4; and Kingsley Biotech (01548) rose 4.46% to HK$14.52.
According to the news, on the afternoon of February 18, Yao Ming Kangde once again issued a clarification notice, reaffirming that it “did not, does not pose a national security risk to the United States in the past, now, and in the future.” The industry believes that although the follow-up actions of US politicians hyping up the drug system will not stop, investors may gradually enter the “desensitization” stage of news related to the US.
Xiangcai Securities pointed out that it is expected that domestic and foreign pharmaceutical R&D spending will continue to grow and that the penetration rate of pharmaceutical R&D outsourcing will continue to increase, which will become an important support for the development of the CXO industry. Although CXO's performance is currently being pressured by the decline in domestic and foreign pharmaceutical investment and financing, given the gradual weakening of expectations of the Federal Reserve's interest rate hike and the clearing of the global biotech sector valuation bubble in the past two years, the cost performance ratio of the global biotech industry has become prominent, and the innovative drug investment and financing environment is expected to gradually pick up, and I am optimistic about the short-term improvement of CXO over the long term.